PADDINGTON
Pharmacodynamic Approaches to Demonstration of Disease-Modification in Huntington’s Disease by SEN0014196
| Coordinatore | SIENA BIOTECH SPA
Organization address
address: Via Banchi di Sotto 34 contact info |
| Nazionalità Coordinatore | Italy [IT] |
| Sito del progetto | http://www.paddingtonproject.eu |
| Totale costo | 8˙589˙885 € |
| EC contributo | 5˙816˙313 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2010-single-stage |
| Funding Scheme | CP-FP |
| Anno di inizio | 2010 |
| Periodo (anno-mese-giorno) | 2010-07-01 - 2013-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
SIENA BIOTECH SPA
Organization address
address: Via Banchi di Sotto 34 contact info |
IT (SIENA) | coordinator | 1˙540˙673.80 |
| 2 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | participant | 2˙001˙045.20 |
| 3 |
UNIVERSITAET ULM
Organization address
address: HELMHOLTZSTRASSE 16 contact info |
DE (ULM) | participant | 1˙104˙681.20 |
| 4 |
KCR SA
Organization address
address: UL. POSTEPU 6 contact info |
PL (WARSZAWA) | participant | 916˙669.90 |
| 5 |
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE
Organization address
address: KEPPEL STREET contact info |
UK (LONDON) | participant | 253˙243.60 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The Consortium will undertake clinical research activities aimed at ascertaining feasibility of a range of pharmacodynamic readouts for use in the clinical development of SEN0014196 to demonstrate the disease-modifying properties of the compound in Huntington’s Disease. SEN0014196 is a novel and selective SirT1 inhibitor, currently in Phase I clinical development, and enjoys Orphan Status in the EU as of September 2, 2009. A multi-factorial approach will be used, including assessment of both novel and compound-specific measures of molecular action as well as previously identified predictors of disease progression. The translational approaches addressed by this project are instrumental in the progression of SEN0014196 to clinical proof-of-concept and, if successful, will play a pivotal role in patient stratification and outcomes research. The Consortium will comprise four partners, all with a proven track-record in Research and Development in the Huntington’s Disease area. All Partners are based within the EU.'
Introduzione (Teaser)
Huntington's disease (HD) is a devastating progressive disorder. Delaying disease onset requires novel targeted interventions early on in life.